A trial of quisinostat for T cell lymphoma of the skin

Cancer type:

Blood cancers

Low grade lymphoma

Lymphoma

Non-Hodgkin lymphoma

Status:

Results

Phase:

Phase 2

This trial looked at quisinostat for cutaneous T cell lymphoma that had come back or got worse after other treatment.

The trial was open for people to join between 2011 and 2012. The team published the results in 2016.

More about this trial

Cutaneous T cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that affects the skin. You may also hear it called mycosis fungoides or Sezary syndrome.

Doctors wanted to find out if quisinostat (JNJ-26481585) was useful for people whose CTCL had come back after other treatment. Quisinostat is a type of treatment called a cancer growth blocker. It blocks the signals that cancer cells need to divide and grow.

Everyone in this trial took quisinostat tablets 3 times a week. They had regular scans to see how well treatment was working. And completed regular quality of life Open a glossary item questionnaires. These asked about any side effects they were having and how they were feeling.

The main aims of this phase 2 trial were to find out:

if quisinostat helps people with cutaneous T cell lymphoma
more about what happens to quisinostat in the body
how quisinostat affects quality of life

Summary of results

As part of our editorial policy, any trial information we write is checked externally before we put it on our website. The research team have published some results for this trial. But we have been unable to find anyone involved with the trial to check the summary for us.

This means we are not able to include a plain English summary of the results on this page.

More information
There is more information about this trial in the link to the medical journal below.

Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.

Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB–IVA mycosis fungoides/Sézary syndrome
F Child and others
British Journal of Dermatology, 2016. Volume 175, issue 1, pages 80–88.